Merck

We’re excited to share pivotal Phase 3 data for our investigational subcutaneous #immunotherapy currently under regulatory review in the U.S. and Europe. These findings are being presented today at #ELCC2025. Read more about our latest news: http://merck.us/4iIS2r8

Today’s EC decision represents a significant milestone to help protect against invasive #pneumococcal disease and pneumococcal #pneumonia. Read more: http://merck.us/3E4YHNf

Today, we announced an exclusive license to develop, manufacture and commercialize an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Atherosclerotic cardiovascular disease (#ASCVD) remains the leading cause of morbidity and death around the world. We have a long history of making an impact in #cardiovasculardisease and this agreement will expand and complement our diverse cardio-metabolic pipeline. Learn more: http://merck.us/4kZRmPL

Thank you to The Wall Street Journal for again including us on its list of the 250 Best-Managed Companies – this time for 2024. Being recognized among such an esteemed group underscores our ongoing commitment to excellence and responsible leadership. We’re proud of the work our team continues to do in support of our purpose, as we remain focused on making a positive impact for patients and all who depend on us.

We’re looking forward to sharing new research aimed at improving outcomes for people living with #cardiovascular disease at #ACC25. Learn more: http://merck.us/4iUFQDq

We’re making an impact beyond the lab by mentoring the next generation of innovators, including our inspiring #WomenInScience. This Women’s History Month, hear advice from some of our scientists about succeeding in #STEM.

Today we shared our latest research on an investigational antiretroviral therapy for adults living with HIV at #CROI2025. Learn more about the results from two Phase 3 trials: http://merck.us/43FzWS8

We have a longstanding commitment to expanding domestic manufacturing and R&D capabilities in the U.S. Our latest $1 billion, 225,000 sq-ft, state-of-the-art facility in Durham, North Carolina, brings that commitment to life by leveraging advanced technical and digital capabilities to enhance our manufacturing process. This facility is part of our more than $12 billion investment in U.S. capital since 2018, and we expect to invest more than $8 billion by the end of 2028. Through innovations and investments, we’ll continue expanding our manufacturing footprint and increasing our production capacity to help more patients. Congratulations to the team on this milestone!

This Employee Appreciation Day, we’re proud to share that we’ve been recognized among Forbes' Best Large Employers, ranking in the top 100 for 2025! Our company is the collective commitment of all our colleagues. We see their hard work and dedication every day, and we’re grateful for opportunities like this to celebrate our team’s ongoing efforts to create a collaborative and innovative workplace. Thanks to all our colleagues for helping fulfill our purpose of saving and improving lives.

In recognition of #InternationalHPVAwarenessDay, we stand alongside global health organizations with the commitment to raise awareness about the impact of certain HPV-related cancers and diseases.